Cardio-oncology & otherCohort study
Human intravenous immunoglobulins for recurrent pericarditis: a multicentre cohort study
- Multicentre cohort study
- registry
- consecutive patients
Authors' conclusion
In patients with RP refractory to the conventional therapy, IVIG were efficacious and safe in reducing further recurrences after failure of other conventional medical therapies.
Study context
- Population
- Patients with recurrent pericarditis after failure of other medical therapies
- Participants
- 43 patients
- Exposure
- Before vs after intravenous immunoglobulins (IVIG)
- Outcome
- Pericarditis recurrence rate after IVIG
Main finding
As reported in the abstract
Recurrences per year, before vs after IVIG · mean follow-up 73 (20-84) months
Recurrences reduced from 1.80 to 0.46 events/year after IVIG
P < 0.001
Observational data: associations, not effects.
Further findings
Clinical remission at discharge
- 40 (93%) patients achieved clinical remission with IVIG
ED admissions per year, before vs after IVIG · mean follow-up 73 (20-84) months
- ED admissions reduced from 0.79 to 0.16 events/year
- P < 0.001
Corticosteroid use, before vs after IVIG
- Corticosteroid use reduced from 72.1 to 19.4%
- P < 0.001
Anakinra use, before vs after IVIG
- Anakinra use reduced from 60.5 to 23.3%
- P < 0.02
Baseline characteristics, recurrence vs no recurrence after IVIG
- No difference in baseline characteristics
Safety
Adverse events
- Discontinued IVIG due to moderate neutropenia, reversible within a few days
- 1
- No serious adverse events
Original publication
Human intravenous immunoglobulins for recurrent pericarditis: a multicentre cohort study. Eur J Prev Cardiol. Published 28 April 2025. doi:10.1093/eurjpc/zwaf250
Summarised from the published abstract; every number is checked against it